© Drug Hunter Inc. 2018-2023
Home > CC-92480
CRBN-based selective IKZF1/3 degrader
oral efficacy in lenalidomide-resist. xenograft
from phenotypic screen and optimization
J. Med. Chem., Mar. 4, 2020
Celgene, San Diego, CA
CC-92480 (Celgene/Bristol Myers Squibb (BMS) oral in vivo CRBN-based selective IKZF1/3 degrader)
You don’t have time to read everything, but you can’t afford to fall behind.
Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.
Get ahead now by requesting a trial.
Molecules of the Month
Molecule of the Year